CHCWM – Cancer & Hematology Centers of West Michigan

INBRX-109 (InhibRx)

An Open Label, Multicenter, First-in-Human, Dose-Escalation Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas